Research programme: antibacterials - Johnson & Johnson
Alternative Names: ARQ 259034; C6-carbamate ketolides research programme - Johnson & Johnson; DQ-1; JNJ 10275798; JNJ 10278385; JNJ 17069546; JNJ 6333314; JNJ-Q1; MurF inhibitors - Johnson & Johnson; RWJ 670963Latest Information Update: 04 Nov 2017
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class Fluoroquinolones; Ketolides; Small molecules
- Mechanism of Action Cell wall inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; MurF synthetase inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 31 May 2010 Antimicrobial data from an in vitro study in Bacterial infections released by Johnson & Johnson Pharmaceutical Research & Development
- 31 May 2010 Preclinical development is ongoing in USA